Suchen
Quoin Pharmaceuticals Ltd
QNRXZur Watchlist hinzufügen
6.900USD
-0.070-1.00%
Handelsschluss 09-10 16:00（ET）
486.44MMarktkapitalisierung
VerlustKGV TTM
Nachbörsliches Trading (ET)0.000USD0.000
Nachbörsliches Trading (ET)mehr Informationen über Quoin Pharmaceuticals Ltd Unternehmen
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Quoin Pharmaceuticals Ltd Profil
BörsenkürzelQNRX
Name des UnternehmensQuoin Pharmaceuticals Ltd
IPO-datumNov 01, 1989
CEOMyers (Michael)
Anzahl der mitarbeiter3
WertpapierartDepository Receipt
GeschäftsjahresendeNov 01
Addresse23 Hata'as Street
StadtKFAR SABA
BörseNASDAQ OMX - NASDAQ BASIC
LandIsrael
Postleitzahl44425
Telefon97299741444
Websitehttps://quoinpharma.com/
BörsenkürzelQNRX
IPO-datumNov 01, 1989
CEOMyers (Michael)
Führungskräfte von Quoin Pharmaceuticals Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael Myers, Ph.D.
Dr. Michael Myers, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
37.71K
+54.33%
Ms. Sally Lawlor
Ms. Sally Lawlor
Chief Financial Officer
Chief Financial Officer
10.68K
+95.88%
Dr. Amotz Nehushtan
Dr. Amotz Nehushtan
Vice President - Research & Development & Product Development
Vice President - Research & Development & Product Development
--
--
Mr. Guy Sapir
Mr. Guy Sapir
Internal Auditor
Internal Auditor
--
--
Dr. Amos Ofer
Dr. Amos Ofer
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Mr. David L. Braun
Mr. David L. Braun
Independent Director
Independent Director
--
--
Mr. Jonathan Burgin, CPA
Mr. Jonathan Burgin, CPA
Independent External Director
Independent External Director
--
--
Ms. Ronit Biran
Ms. Ronit Biran
Independent Director
Independent Director
--
--
Mr. Yali Sheffi
Mr. Yali Sheffi
Independent External Director
Independent External Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael Myers, Ph.D.
Dr. Michael Myers, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
37.71K
+54.33%
Ms. Sally Lawlor
Ms. Sally Lawlor
Chief Financial Officer
Chief Financial Officer
10.68K
+95.88%
Dr. Amotz Nehushtan
Dr. Amotz Nehushtan
Vice President - Research & Development & Product Development
Vice President - Research & Development & Product Development
--
--
Mr. Guy Sapir
Mr. Guy Sapir
Internal Auditor
Internal Auditor
--
--
Dr. Amos Ofer
Dr. Amos Ofer
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Mr. David L. Braun
Mr. David L. Braun
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Quoin Pharmaceuticals Ltd?
Die fünf größten Anteilseigner von Quoin Pharmaceuticals Ltd sind: Dr. Michael Myers, Ph.D.
Wie viele Institutionen halten Anteile an Quoin Pharmaceuticals Ltd (QNRX)?
Mit Stand vom 2026Q1 halten 40 Institutionen Anteile an Quoin Pharmaceuticals Ltd, mit einem Gesamtmarktwert von etwa 874.98K, was 43.66% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 369388.00 gestiegen.